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Abstract
Modifications occurring on autoantigens during cell death have 
been proposed to have a role in the initiation of autoimmune 
diseases. Patients suffering from mixed connective tissue 
disease (M CTD) produce autoantibodies directed to U 1 small 
nuclear ribonucleoprotein (snRNP), and antibodies against a 70  
kDa protein component, the U1-70K (70K) protein, are the most 
prominent. During apoptosis, 70K is cleaved by caspase-3 to a 
40 kDa product, which remains associated with the complex. 
Autoantibodies preferentially recognizing the apoptotic form of 
70K have been described previously, and an apoptosis-specific 
epitope on 70K has been identified. This study shows that 29 of 
53 (54%) MCTD sera preferentially recognize the apoptotic
form of 70K over intact 70K. Moreover, we show that antibodies 
directed to an apoptosis-specific epitope on 70K are more 
specifically associated w ith MCTD than other anti-70K 
antibodies, suggesting that apoptotic 70K is a better antigen for 
the detection of these antibodies in MCTD patients. 
Longitudinal analysis of 12 MCTD patients showed in several 
patients that early sera are relatively enriched with antibodies 
recognizing an apoptosis-specific epitope, and that the levels of 
these apoptosis-specific antibodies decrease in time. These 
findings indicate that the early detection of apoptotic 70K is of 
considerable interest for anti-U1 snRNP-positive patients.
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Introduction
Patients suffering from autoimmune diseases are charac­
terized by the presence of autoantibodies directed to a 
wide range of autoantigens. Mixed connective tissue dis­
ease (MCTD) is a relatively rare systemic autoimmune dis­
ease and includes a group of patients with overlapping 
clinical symptoms of systemic lupus erythematosus (SLE), 
systemic sclerosis (SSc), rheumatoid arthritis and polymy­
ositis/dermatomyositis. Sharp and colleagues were the first 
to describe MCTD as a distinct rheumatic disease [1], but 
whether MCTD can be regarded as a distinct disorder has 
been a subject of discussion [2]. A characteristic serologi­
cal feature that distinguishes MCTD patients from patients 
with other connective tissue diseases is high levels of
autoantibodies directed against the U1 small nuclear ribo- 
nucleoprotein (snRNP) particle [1,3]. The U1 snRNP is a 
highly conserved RNA-protein complex, located in the 
nucleus, where it is involved in the processing of pre-mRNA 
[4,5]. It consists of the U1 snRNA molecule and several 
proteins: the U1A, U1C and U1-70K (70K) proteins are 
components specific for the U1 snRNP, whereas the seven 
Sm proteins (B/B', D1, D2, D3, E, F and G) are shared with 
other U snRNPs [6]. Most U1 snRNP components are 
autoantigenic in MCTD and SLE. Autoantibodies directed 
against U1A, U1C, 70K and the U1 snRNA molecule are 
mainly found in MCTD patients, whereas autoantibodies 
targeting Sm-D, Sm-B/B' and the E.F.G complex are more 
specifically associated with SLE [7,8].
70K =  U1-70K; 70Kapop =  apoptotic cleavage product of U1-70K protein of about 40 kDa; MCTD =  mixed connective tissue disease; NP40 =  Nonidet 
P40; RNP =  ribonucleoprotein; SLE =  systemic lupus erythematosus; snRNP =  small nuclear ribonucleoprotein; SSc =  systemic sclerosis; U1-70K 
=  70 kDa protein component of the U1 snRNP complex. R302
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The mechanisms through which such autoantigens, gener­
ally highly conserved and ubiquitously expressed mole­
cules, escape tolerance and are recognized by the immune 
system as non-self remain unclear, but it is proposed that 
cell death is important in the initiation of autoimmune 
responses [9,10]. Recently, secondary necrosis has also 
been put forward as a source of proteolytically modified 
autoantigens [11], but the modifications that occur on 
autoantigens during apoptosis were studied most exten­
sively. Apoptotic modifications on autoantigens include 
specific cleavage by caspases or granzyme B, 
(hyper)phosphorylation, dephosphorylation, citrullination, 
methylation and transglutaminase cross-linking [10,12,13], 
and it is thought that these modifications might be seen by 
the immune system as novel 'cryptic' epitopes. It is believed 
that these novel epitopes induce the primary immune 
response, and that secondary immune responses and 
epitope spreading result in autoantibodies that are directed 
against unmodified regions of the autoantigens and anti­
gens that are associated with the initially modified autoan­
tigen [9].
One of the apoptotic modifications occurring on the U1 
snRNP is the cleavage of 70K at residue 341 by caspase-
3 [14,15]. Antibodies against 70K are in general the first 
autoantibodies to appear in anti-U1 snRNP (often referred 
to as anti-RNP) positive patients, indicating that 70K is 
important as an initial autoantigen [16]. The molecular and 
immunological characteristics of the major apoptotic iso­
form of 70K, a 40 kDa cleavage product that remains asso­
ciated with the U1 snRNP complex [17], and its role in the 
triggering of the primary and possibly secondary autoim­
mune response, are therefore intriguing.
Recently it was shown that sera of some anti-U 1 snRNP 
positive patients contain antibodies that specifically bind to 
the apoptotic form of 70K, which displays an epitope that 
is not present on the intact form [18,19]. This epitope is 
dependent on the region between amino acids 180 and 
205, partly overlapping with the RNA-binding domain and 
overlapping with the most common T cell epitope [20]. In 
this study we analyzed a cohort of MCTD and control 
patients for the presence of autoantibodies against intact 
and apoptotic 70K. Moreover, we longitudinally analyzed 
sera from another group of MCTD patients. Our results 
show that, early in disease, autoantibodies directed against 
the apoptotic form of 70K (70Kapop) are more strongly rep­
resented than autoantibodies against the intact form. Lon­
gitudinal studies also show that autoantibodies against 
70Kapop are not significantly correlated with disease flares.
Methods
Patient sera
All patients were seen at the Department of Rheumatology 
of the University Medical Centre Nijmegen or the St
Maartenskliniek Nijmegen (The Netherlands), and were 
classified in accordance with standard criteria for each dis­
ease. All MCTD patients (n =  53) tested positive for anti- 
U1 snRNP autoantibodies by counter-immunoelectro- 
phoresis, and for antibodies against one or more compo­
nents of the U1 snRNP complex by immunoblotting. Most 
of the sera (91%) were also RNP positive as shown by U1 
snRNA co-immunoprecipitation. Longitudinal serum collec­
tions were obtained from 12 MCTD patients and have been 
described previously [21]. From each patient, over a period 
of 4 -1 5  years (average 10 years), 8 to 33 serum samples 
(average 18 samples) were available and were analyzed. 
During the follow-up study, the patients were regularly mon­
itored for clinical and serological parameters. At each visit 
the disease activity was measured in accordance with a val­
idated SLE disease activity index described by Ter Borg 
and colleagues [22]. Medication was given as indicated by 
the clinical status. Additionally, patient sera were collected 
from SLE (n =  48), polymyositis/dermatomyositis (n =  26), 
primary Sjögren's syndrome (n =  18), SSc (n =  10), rheu­
matoid arthritis (n =  3), Raynaud's phenomenon (n =  3) and 
undefined connective tissue disease (n =  1). Informed con­
sent was obtained from all participants in accordance with 
the medical ethical regulations of the local ethics commit­
tee. Sera were stored at -70°C until use.
Cell lines, induction of cell death and preparation of cell 
extracts
Jurkat (human T cell leukemia) suspension cells were 
grown in RPMI 1640 medium (Gibco-BRL), supplemented 
with 1 mM sodium pyruvate, 1 mM penicillin, 1 mM strepto­
mycin and 10% heat-inactivated fetal calf serum (Gibco- 
BRL), in a humidified 37°C incubator containing 5% C O 2. 
Cells were maintained at a concentration of 106 cells/ml 
and were induced to undergo apoptosis by the addition of
10 |ig/ml anisomycin. Eight hours after induction, apoptotic 
cells were harvested by centrifugation at 800 g for 10 min 
and washed with PBS. Apoptotic and non-apoptotic Jurkat 
cells were resuspended in Nonidet P40 (NP40)-containing 
lysis buffer (25 mM Tris-HCl, pH 7.6, 100 mM KCl, 10 mM 
MgCl2, 0.25 mM dithioerythritol, 1% NP40, Complete™ 
protease inhibitor cocktail [Roche]) at a concentration of 
108 cells/ml. Cells were lysed on ice for 30 min and subse­
quently centrifuged for 30 min at 12,000 g and 4°C. Super- 
natants were used immediately or stored at -70°C.
SDS-polyacrylamide gel electrophoresis and western 
blotting
Cell extracts of 1.3 x  107 non-apoptotic Jurkat cells and 1.3 
x  107 apoptotic Jurkat cells, either separately or mixed, 
were separated by SDS-polyacrylamide gel electrophore­
sis. Directly after gel electrophoresis, proteins were trans­
ferred to a nitrocellulose membrane (Schleicher & Schuell) 
by semi-dry electroblotting. Staining of the membrane with 
Ponceau S (Sigma) was used to verify protein transfer.
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Probing western blots with patient sera
All incubation steps were performed at approximately 20°C 
on a shaking table. Western blots containing non-apoptotic 
and apoptotic Jurkat cell extracts were pre-blocked with 
5% non-fat dried milk in PBS containing 0.1% NP40 
(MPBS/NP40) for 2 hours. Subsequently, membranes 
were incubated with patient serum, diluted 1000 -5000 ­
fold in MPBS/NP40, for 1 hour. After extensive washing 
with PBS containing 0.1% NP40 (PBS/NP40), mem­
branes were incubated with horseradish peroxidase­
labeled rabbit anti-human IgA/IgG/IgM antibody (Dako 
Immunoglobulins), diluted 1000-fold in MPBS/NP40, for 1 
hour. After several washes with PBS/NP40 and PBS, 
bound antibodies were detected by enhanced chemilumi- 
nescence. Antibody reactivities against 70K and 70Kapop 
were scored ranging from 0 to 5 by three researchers inde­
pendently. In each experiment several control antibodies 
were used.
Results
In this study, patient sera were analyzed for the presence of 
autoantibodies against 70K and its apoptotic product 
(70Kapop), on western blots containing extracts of non- 
apoptotic and apoptotic Jurkat cells. Two positive controls 
for the detection of 70K and 70Kapop were included in each 
experiment: anti-70K mouse monoclonal antibody 2.73 
[23], which displays higher reactivities with 70K than with 
70Kapop, and serum from MCTD patient B16, which reacts 
with both 70K and 70Kapop. The position of 70Kapop on 
western blots was confirmed by a recombinant monoclonal 
antibody recognizing both 70K and 70Kapop (Fig. 1a) [24]. 
The results show that in these apoptotic cells 70K is con­
verted almost completely into 70Kapop. Besides positive 
controls for 70K and 70Kapop, mouse monoclonal antibody 
ANA125 directed against Sm-B/B' (Fig 1a), and anti-U1-A/ 
U2-B" mouse monoclonal antibody 9A9 (not shown) were 
also used. To be able to detect autoantibody reactivities to 
the intact 70K and its apoptotic 40K fragment simultane­
ously and to facilitate a direct comparison of these reactiv­
ities, a mixture of apoptotic and non-apoptotic cell extracts 
was used to prepare western blots. An additional advan­
tage of this approach was that differences between blots 
could be excluded, thereby allowing a more accurate com­
parison of reactivities with 70K and 70Kapop in a single 
patient serum. Serum antibody reactivities against 70K and 
70Kapop were scored ranging from 0 to 5. Figure 1b shows 
a western blot containing such a mixture of non-apoptotic 
and apoptotic Jurkat cell extracts, probed with a serial dilu­
tion of serum from MCTD patient B16. It can be seen that 
the signals for 70K and 70Kapop increase when the serum 
is applied at a lower dilution, indicating that the western 
blot assay can be used for semi-quantitative interpretation.
Autoantibodies against 70K are more easily detected 
with 70Kap°p
The presence of high levels of autoantibodies directed 
against components of the U1 snRNP, such as 70K, is one 
of the criteria for the diagnosis of MCTD [2]. However, anti- 
70K antibodies are also found in some SLE and SSc 
patients [3]. To compare the disease specificity of anti- 
70Kapop and anti-70K autoantibodies, sera from a group of 
MCTD patients and from a group of patients suffering from 
a variety of autoimmune disorders were analyzed. As shown 
in Table 1, most MCTD patients (54%) displayed antibody 
reactivities that preferentially recognized 70Kapop over the 
intact 70K protein. Seven patients (13%) reacted with 70K 
and 70Kapop with similar efficiencies, and only 6% of the 
MCTD patients reacted preferentially with the intact 70K 
protein. Fourteen sera (27%) did not react detectably with 
either 70K polypeptide, although the sera were anti-RNP 
positive by several techniques. These results indicate that 
70Kapop is a better antigen than the intact 70K protein for 
the detection of anti-70K autoantibodies. Antibody reactiv­
ity with 70Kapop was found in only 2% of sera from control 
groups, whereas antibody reactivity with 70K was found in 
5% of patient sera from control groups.
Autoantibodies against 70Kapop are not correlated with 
disease activity
It has been described that, in some patients with MCTD, 
antibody titers against the U1 snRNA molecule are corre­
lated with disease activity, and could even possess prog­
nostic value [21]. In contrast, most studies did not find a 
correlation between disease activity and antibody 
responses to 70K, either by serum analysis using recom­
binant protein as antigen in ELISA [21,25] or by analysis on 
western blots using native protein from cell extracts [26]. 
Only one study, using ELISA with recombinant 70K as 
technique, has reported decreasing disease activity con­
comitant with decreasing anti-70K antibody levels [27]. 
Because apoptotic modifications on autoantigens, such as 
the cleavage of 70K, are believed to be involved in the pri­
mary autoimmune response, we proposed that immune 
complexes containing anti-70Kapop antibodies might also 
be important for triggering disease flares. Serum samples 
were collected longitudinally from 12 MCTD patients by a 
follow-up during variable time intervals (4 -15  years; aver­
age 10 years). All samples were analyzed for the presence 
of autoantibodies against 70K and 70Kapop on western 
blots containing non-apoptotic and apoptotic Jurkat cell 
extracts, and the presence of these autoantibodies was 
compared with the disease activity of each patient. The 
overall conclusion of this longitudinal study was that no sig­
nificant correlations between antibody titres against either 
70Kapop or 70K and disease exacerbations could be 
observed.
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F igure  1
Anti-U1-70K and anti-70KaP°P detection by western blotting. Apoptosis was induced in Jurkat cells by incubation with anisomycin for 8 hours. W est­
ern blots were prepared with the resulting cell extracts, and the positions of relevant polypeptides were revealed with patient sera and monoclonal 
antibodies with the use of a chemiluminescent detection procedure. The positions of the various proteins are indicated on the left, and molecular 
mass marker positions on the right. (a) U1-70K (70K) detected with a serum from MCTD patient B16 (lanes 1 and 5), anti-70K monoclonal antibody 
2.73 (lanes 2 and 6) and an anti-70K single-chain recombinant antibody (scFv; lanes 3 and 7) (70K); lanes 4 and 8, Sm-B/B' detected with a mono­
clonal anti-Sm-B/B' antibody (ANA125); the position of U1A, which is also recognized by serum from MCTD patient B16 (lanes 1 and 5), was deter­
mined by a U1A-specific monoclonal antibody (not shown). In apoptotic cells (lanes 5 -8 ), 70K is present as a 40 kDa species (70Kap°P). (b) A 
serum sample from MCTD patient B16 was applied at 5000-fold (lane 1), 10,000-fold (lane 2) and 20,000-fold (lane 3) dilution on a western blot 
containing a mixture of non-apoptotic and apoptotic Jurkat cell extracts. In lane 4 the 70K protein was detected with mouse monoclonal antibody 
2.73, which reacts much more efficiently with 70K than with 70KaP°P.
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Table  1
R ecogn ition  o f U1-70K (70K) and its  a p o p to tic  c leavage p roduc t (70KaP°P) by pa tie n ts  w ith  d iffe re n t au to im m u n e  d isorders
No. (%) of patients with disorder
Patient group (disease) No. of patients 70Kapop 70Kapop >  70K 70Kapop =  70K 70K >  70Kapop 70K
MCTD 53 15 (28) 14 (26) 7 (13) 1 (2) 2 (4)
SLE 48 0 1 (2) 1 (2) 0 1 (2)
Non-SLEa 61 0 0 0 0 2 (3)
aThe control group of non-systemic lupus erythematosus (non-SLE) patients consists of patients suffering from polymyositis/dermatomyositis (n =  
26), primary Sjögren's syndrome (n =  18), systemic sclerosis (n =  10), rheumatoid arthritis (n =  3), Raynaud's phenomenon (n =  3) and undefined 
connective tissue disease (n =  1). MCTD, mixed connective tissue disease.
F igure  2
7 0 K = * | m  C  I
Longitudinal anti-70K analysis of patient T2. Eighteen serum samples taken over a period of 7 years with approximately equal time intervals were 
analyzed on western blots containing non-apoptotic and apoptotic Jurkat cell extracts. The positions of U1-70K (70K), of which two isoforms are vis­
ible, and 70Kapop are indicated on the left. In lane 19, 70K was detected with mouse monoclonal 2.73, which reacts much more strongly with 70K 
than with 70Kapop. MoAb, monoclonal antibody.
Autoantibodies against 70Kapop are more prevalent early 
in disease
As mentioned above, it has been proposed that apoptotic 
modifications trigger the primary immune response 
towards self proteins and that, through secondary immune 
responses and epitope spreading, autoantibodies directed 
against unmodified regions on the autoantigen appear at 
later stages of the disease. To investigate this possibility for 
the 70K autoantigen, the longitudinal serum collection [21] 
of 12 MCTD patients was re-examined, now for antibodies 
against 70K and for antibodies against 70Kapop. Three 
patients produced antibodies reacting strongly with 
70Kapop, whereas no or only weak reactivity against 70K 
was observed. In one of these three patients, autoantibod­
ies against 70Kapop were more prevalent in early serum 
samples, and the level decreased in time. Eight patients 
were found to have high titres of antibodies with reactivities 
to both 70K and 70Kapop. Interestingly, in three of these 
patients early serum samples showed a higher reactivity 
with 70Kapop than with 70K, whereas later samples showed 
comparable reactivities with both antigens, or higher reac­
tivities with 70K. An example of this type of reactivity profile 
is shown in Fig. 2. One of the 12 patient sera did not 
detectably contain antibodies directed against 70K or 
70Kapop. These results thus support the idea that antibod­
ies against 70Kapop appear earlier in the disease than anti­
bodies against the complete 70K protein.
Discussion
Greidinger and colleagues recently showed that antibodies 
against the 70K protein in RNP-positive patients are often 
accompanied by antibodies directed against the apoptotic 
cleavage product of this autoantigen and that the B cell 
epitopes recognized on the apoptotic product are antigen- 
ically different from those contained in the intact form of the 
70K protein [18,19]. This study is the first to confirm and 
extend these findings and strongly suggests that the reac­
tivity of a patient serum with anti-70K antibodies depends 
on the presence of antibodies against epitopes shared by 
70K and 70Kapop, and on the presence of antibodies 
against epitopes exclusively present on 70Kapop. The major 
apoptosis-specific epitope on 70K has been shown to be 
located in the region containing the RNA-binding domain, 
and its formation depends on amino acids 180-205, over­
lapping with the most common T cell epitope [20]. Other 
apoptosis-specific epitopes on 70K have not yet been 
described. In our recent studies, monoclonal recombinant 
human antibodies against 70K were isolated from phage 
display libraries derived from SLE patients, and several of 
these monoclonal antibodies preferentially recognized
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70Kapop on a western blot and in immunoprecipitation 
experiments ([24], and D Hof, unpublished results). It is 
believed that the apoptotic cleavage of 70K leads to the 
exposure of a neo-epitope that, if presented to the immune 
system, triggers the autoimmune response. Greidinger and 
colleagues showed that a mutant consisting of the amino- 
terminal 205 amino acids, was indeed able to induce an 
anti-70Kapop antibody response in mice, with subsequent 
epitope spreading. Interestingly, some of the immunized 
mice developed pulmonary lesions comparable to lesions 
found in lungs of MCTD patients. This finding supports the 
hypothesis that apoptosis-specific epitopes, and antibod­
ies directed against them, might have a pathological role in 
the triggering and maintenance of the human autoimmune 
response to 70K [19].
In our study, a minority of MCTD sera (4%) contained 
autoantibodies exclusively reacting with intact 70K. We 
suggest that these sera derive from patients in a relatively 
late disease phase and primarily contain antibodies result­
ing from expanded epitope spreading. Most epitopes rec­
ognized by these sera might therefore be dependent on the 
carboxy-terminal part of the protein, which is cleaved off 
during apoptosis and is not present on 70Kapop. Patients 
that tested negative in our western blot experiments might 
either have low levels of anti-70K antibodies or might not 
produce such antibodies at all. Instead, other components 
of the U1 snRNP, such as the U1 RNA molecule, U1A or 
U1C, might be targeted by these sera and might explain 
their anti-U 1 snRNP reactivity.
We show here that most U1 snRNP-positive patient sera 
preferentially recognize 70Kapop, which is most probably 
explained by the presence of antibodies targeting an apop­
totic 70K epitope. These results are in line with reports by 
Greidinger and colleagues [18,19], who found that about 
50% of their RNP-positive sera contained 70Kapop autoan­
tibodies.
How disease flares are induced is not completely under­
stood. Correlations between serum levels of certain 
autoantibodies and disease activity have been reported for 
MCTD and SLE [21,22], but it can be disputed whether 
these antibodies contribute to the disease flares or are 
merely epiphenomena. Our data show that antibodies 
against 70Kapop are not significantly correlated with disease 
activity, suggesting that there is no important role for 
70Kapop in the initiation of disease flares. However, it is pos­
sible that the variations in antibody levels against the apop- 
tosis-specific epitope are masked by the presence of 
antibodies against other epitopes on 70K and U1-70Kapop. 
Furthermore, a polyspecific secondary antibody was used 
to detect bound serum antibodies, and as a consequence 
variations in isotype-specific antibody levels might have 
remained undetected.
It has been reported that the first autoantibodies to appear 
in anti-RNP-positive patients are generally antibodies 
against 70K [16,27]. Our results suggest that 70Kapop 
drives the primary autoimmune response to 70K, because 
in several patients antibodies against an epitope associ­
ated with 70Kapop preceded the appearance of reactivity 
with intact 70K. The fact that the first serum samples from 
relatively few patients exclusively contain anti-70Kapop anti­
bodies might be due to the stage of disease development 
at which the patient enters the rheumatological clinic. It is 
likely that the first symptoms, later followed by the diagno­
sis of the disease, had been established years before the 
start of the longitudinal study. Moreover, it is possible that 
autoantibodies, especially those generated by the primary 
immune response, were already present before the mani­
festation of clinical symptoms and that subsequent epitope 
spreading might have occurred before the patient entered 
the rheumatological clinic. For example, anti-cyclic citrulli- 
nated peptide autoantibody is a very specific marker for 
rheumatoid arthritis, and such antibodies can be detected 
in patients up to 10 years before the occurrence of the first 
clinical symptoms [28,29]. In our opinion this might explain 
why a relative enrichment of anti-70Kapop antibodies could 
not be detected in the early sera of all patients.
During apoptosis, the U1 snRNP complex is modified in 
several ways. In addition to cleavage of 70K, U1 snRNA 
and the Sm-F protein are cleaved, and phosphorylated ser- 
ine-arginine proteins associate with the complex [30]. 
Apoptotic modifications of the U1A and U1C proteins have 
not yet been described. 70K can be cleaved by caspase-3 
and granzyme B, and it can be oxidatively fragmented in the 
presence of metals, resulting in products of 40, 60 and 55 
kDa, respectively. Correlations between the recognition of 
specific 70K fragments and disease manifestations are 
interesting. For example, patients suffering from Raynaud's 
phenomenon preferentially recognize the oxidatively modi­
fied 55 kDa fragment of 70K [31]. The findings that early 
MCTD sera are enriched for antibodies against the 40 kDa 
apoptotic fragment (70Kapop) and that most sera show a 
higher reactivity with this fragment suggest that caspase-3 
cleaved 70K has a role in breaking tolerance in these 
patients. Although granzyme B is postulated to have a role 
in breaking tolerance [32] to 70K, it is unknown whether 
specific patient groups preferentially recognize the 60 kDa 
cleavage product generated by granzyme B, which would 
be interesting to study in more detail.
Conclusions
Analysis of a group of MCTD patient sera by western blot­
ting showed that the majority of patient sera recognized 
70Kapop more efficiently than the intact form of the 70K 
protein. The fact that the presence of these antibodies in 
most patients precedes the occurrence of other anti-70K
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antibodies suggests that 70Kapop is particularly important 
for the early detection of this disease in patients.
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